Introduction
Despite concern about its toxicity chloramphenicol is widely used to treat neonatal meningitis.' Three types of toxicity have been described-namely, the grey baby syndrome,2 reversible dose related haemopoietic disturbances,3 and idiopathic marrow aplasia unrelated to dosage.4 Serum chloramphenicol concentrations between 40 and 200 mg/l have been reported in association with the grey syndrome,5 6 and reversible bone marrow suppression related to dosage may occur when serum concentrations exceed 25 mg/l.3 Irreversible marrow aplasia is a rare complication (incidence 1/20 000 to 1/80 000 patients treated) and has a high mortality. Its occurrence is unpredictable.
The incidence of dose related chloramphenicol toxicity in the newborn is unknown. There is no general agreement on the desirable therapeutic range of chloramphenicol concentrations, -but serum concentrations of 10-20 mg/P7 and 15-25 mg/P8 are often quoted. As the minimum inhibitory concentration of chloramphenicol for some Gram negative rods may be as high as 6 mg/l and only 30-60% of the drug crosses the meninges it would seem more appropriate to maintain serum concentrations in the range 15-25 mg/l provided that such concentrations are not associated with toxic manifestations.
In this study, which was carried out between March 1978 and August 1981, we determined the incidence of dose related chloramphenicol toxicity in 64 neonates receiving chloramphenicol for life threatening infections. We assessed the value of measuring serum concentrations of the drug and the possibility of predicting toxic effects and establishing the therapeutic range of chloramphenicol concentrations.
Patients and methods
Study population-We studied 64 neonates (less than 28 days old) from 12 hospitals who formed part of a larger study on The second baby, for whom 9 3 mg/kg every six hours (37 mg/kg/day) was prescribed, showed no symptoms of toxicity despite having a serum concentration of 65 mg/l seven and a half hours after the overdose. The remaining neonate (prescribed dose 24 mg/kg/day) received a dose of 80 mg/kg. The only adverse effect was acidosis, and after 40 hours treatment was restarted. Blood chloramphenicol concentration five hours after the overdose was 40 mg/l. Serum chloramphenicol concentrations below 25 mg/l were recorded in both these latter babies within [14] [15] [16] [17] [18] [19] [20] [21] [22] hours. The figure shows the concentration time curves in these three neonates. One baby received 40 mg were prescribed 60 and 50 mg/kg/day (recommended dosage 37-5 and 25 mg/kg/day respectively), showed no signs of toxicity despite a peak concentration of 90 mg/l in one and a concentration of 31 mg/l 17 hours after injection in the other. The remaining 49 babies showed no obvious toxic signs or symptoms resulting from chloramphenicol treatment. Table II shows serum chloramphenicol concentrations and dosage schedules in 45 of these neonates; data from four babies could not be evaluated. Peak chloramphenicol concentrations > 25 mg/ 1 or trough concentrations > 15 mg/l, or both, were observed in 23 of these neonates, 16 of whom were given more than the recommended dose. Three of these babies had concentrations greater than 50 mg/l. Table III shows the relation between dosage, high serum concentrations, and toxicity.
The 10 babies who showed signs of chloramphenicol toxicity had normal renal function before treatment. During treatment oedema, hyponatraemia, and reduced urine output were recorded in four, two of whom were found later to have inappropriate secretion of antidiuretic hormone. 
Discussion
The present study has shown that many neonates (27/37) can tolerate serum chloramphenicol concentrations above 25 mg/l with no clinical signs of toxicity. Seven of these 27 babies had serum concentrations in excess of 50 mg/I. No relation could be established between the duration of high serum concentrations and toxicity. The effect of high serum concentrations may be related to age, as nine of the 10 babies who showed toxic signs were less than nine days old while four of the seven with serum concentrations >50 mg/l but no toxicity were more than 20 days old. High serum concentrations in the absence of toxicity have been reported in a 10 week old baby. '5 Our results suggest that chloramphenicol may be used safely to treat neonates if serum concentrations are maintained in the range 15-25 mg/I, as no babies with concentrations in this range showed signs of toxicity. Symptoms of the grey syndrome were associated with very high serum concentrations (35-180 mg/i), which are unlikely to occur unless an overdose has been administered or the prescribed dosage is well above that recommended. Reversible haematological side effects occurred at lower serum concentrations, which were nevertheless outside the therapeutic range, and were not associated with prolonged treatment. Predicting those at risk of haematological effects is difficult.
The delayed clearance of chloramphenicol in neonates is thought to be due to inefficient glucuronidisation in the liver and reduced renal elimination of the metabolite."6 Poor renal function would result in both reduced elimination of active chloramphenicol by glomerular filtration and reduced elimination of the parent ester, which would remain in the body and subsequently undergo hydrolysis to active drug. Our results indicate that one manifestation of the grey syndrome is reduced renal output resulting in persistent high serum concentrations. Probably poor renal function is just as important as low activities of liver enzymes in maintaining high chloramphenicol concentrations.
The assertion that active chloramphenicol, rather than the parent compound or its metabolites, causes toxicity in the neonate is widely accepted but is based on indirect evidence. Adult patients with anuria accumulate high concentrations of glucuronide metabolite with no evidence of toxicity,'l7 and large doses of chloramphenicol glucuronide have been administered to rats without toxic reactions. Chloramphenicol glucuronide concentrations in neonates have not been determined.
Tenfold overdoses administered to three babies in this study were the result of the decimal point being misread when the injections were drawn up from a 1-2 g phial (100 g/l Multiple exchange transfusions have been advocated as effective treatment for severe chloramphenicol intoxication,"8 but two exchange transfusions in one subject in the present study (figure) had little effect on serum chloramphenicol concentrations. Charcoal column haemoperfusion has been used with dramatic effect in one term neonate, reducing serum concentrations from 98 mg/l to 13 5 mg/l in three hours, but this treatment may have side effects. '9 In the present study serious toxicity was associated with either overprescription or overdosage of chloramphenicol in most cases. Thus high serum chloramphenicol concentrations and their associated toxicity in young neonates may be avoided by prescribing the recommended dose initialLy' 14 Patients, methods, and results I posted questionnaires to the 600 runners who registered for the 1983 Guildford marathon. The questionnaires established the age, sex, number of previous marathons, weekly training milage, and the presence of gastrointestinal symptoms and blood in vomit, urine, and stools. Of the 600 runners 415 showed their intention to run the full marathon by entering the second circuit of the course, and 386 completed the race. Of the 415 (287 men and 12 women) 299 (72%) returned their questionnaires. In a preliminary study three runners who had taken part in a different marathon and were not entered for the Guildford marathon submitted to a hospital laboratory stool specimen taken before and after the marathon race. One of these three runners (a slow veteran) gave positive results for melaena after the race, though not before. He later ran in another marathon and again these results became positive.
In this study 10% of the original applicants were randomly selected and asked to test their urine for the presence of blood immediately after the race with a reagent strip (Labstix) and to provide stool smears taken before and after the race to test for the presence of occult blood (Hema-Chek). Samples were returned by 36 runners (about 54% of those eligible). None of them reported frank haematuria, but two had reagent strips giving positive results. These, however, do not discriminate between red blood cells, haemoglobin from march haemoglobinuria, or myoglobin, which may be produced in quantity during vigorous exercise.4 Only one runner (a young slow man) reported tarry stools. Two men (one young and fast, and one a slow veteran) with negative test results for melaena before the race gave definitely positive results after it. A further man (young and fast) had a weakly positive smear after the race. None of the smears was positive before the race. One runner gave positive results with both the urine reagent strip and stool smear. None of the runners with a positive stool smear result admitted to piles.
Comment
Only one of the 299 runners studied noted a tarry stool, but three (8%) of 39 (including those in the preliminary study) passed stools after racing which gave positive results for melaena. This suggests that unrecognised bleeding into the gut during a marathon is not uncommon. Contributory factors may include an unsuspected local cause such as piles, damage to intraabdominal hollow organs from repetitive impact of a free surface against a fixed surface such as has been described for the bladder,1 relative ischaemia of the gut wall caused by diversion of the splanchnic circulation,2 and trauma haemolysis in the feet which might trigger disseminated intravascular coagulation with some consumption of coagulation factors and cause a predisposition to bleeding. The aetiology of the mild anaemia found in some distance runners is obscure,5 but repeated oozing into the gut during training and racing may be a factor. I Prior treatment with systemic antihistamine preparations suppresses pruritus induced by histamine' and allergens2 and diminishes wheal size.3 It is common practice to applya topical antihistamine preparation for symptomatic relief after skin testing with allergens, although the benefits of this have not been tested. We report a double blind controlled trial of mepyramine maleate cream versus placebo cream applied after skin testing in patients with atopy.
Patients, methods, and results
Skin prick tests were performed on both arms of 32 patients with atopy using the following Bencard allergens: house dust mite, grass and tree pollen, cat and dog fur, feathers, and aspergillus; positive (histamine) and negative controls were also used. After 10 minutes we recorded the diameter in millimetres of the largest wheal and the intensity of erythema on a visual analogue scale ranging fron "no erythema" to "intense erythema" on a 100
